666 related articles for article (PubMed ID: 25830489)
21. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
[TBL] [Abstract][Full Text] [Related]
22. A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and Malaysia.
Lim FS; Koh MT; Tan KK; Chan PC; Chong CY; Shung Yehudi YW; Teoh YL; Shafi F; Hezareh M; Swinnen K; Borys D
BMC Infect Dis; 2014 Oct; 14():530. PubMed ID: 25278086
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants.
Ruiz-Palacios GM; Guerrero ML; Hernández-Delgado L; Lavalle-Villalobos A; Casas-Muñoz A; Cervantes-Apolinar Y; Moreira M; Schuerman L
Hum Vaccin; 2011 Nov; 7(11):1137-45. PubMed ID: 22048109
[TBL] [Abstract][Full Text] [Related]
24. Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial.
Dicko A; Odusanya OO; Diallo AI; Santara G; Barry A; Dolo A; Diallo A; Kuyinu YA; Kehinde OA; François N; Borys D; Yarzabal JP; Moreira M; Schuerman L
BMC Public Health; 2011 Nov; 11():882. PubMed ID: 22112189
[TBL] [Abstract][Full Text] [Related]
25. Anamnestic immune response in 3- to 4-year-old children previously immunized with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as 2-dose or 3-dose priming and a booster dose in the first year of life.
Silfverdal SA; Skerlikova H; Zanova M; Papúchová D; Traskine M; Borys D; Schuerman L
Pediatr Infect Dis J; 2011 Sep; 30(9):e155-63. PubMed ID: 21572373
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants.
Odutola A; Ota MOC; Antonio M; Ogundare EO; Saidu Y; Owiafe PK; Worwui A; Idoko OT; Owolabi O; Kampmann B; Greenwood BM; Alderson M; Traskine M; Swinnen K; Verlant V; Dobbelaere K; Borys D
Vaccine; 2019 May; 37(19):2586-2599. PubMed ID: 30975570
[TBL] [Abstract][Full Text] [Related]
27. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
Knuf M; Szenborn L; Moro M; Petit C; Bermal N; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S97-S108. PubMed ID: 19325452
[TBL] [Abstract][Full Text] [Related]
29. Can two different pneumococcal conjugate vaccines be used to complete the infant vaccination series? A randomized trial exploring interchangeability of the 13-valent pneumococcal conjugate vaccine and the pneumococcal non-typeable
de Los Santos AM; Rodríguez-Weber MA; Sánchez-Márquez P; Traskine M; Carreño-Manjarrez R; Cervantes-Apolinar MY; Strezova A; Ruiz-Guiñazú J; Ortega-Barria E; Borys D
Expert Rev Vaccines; 2020 Nov; 19(11):995-1010. PubMed ID: 33297773
[No Abstract] [Full Text] [Related]
30. Pneumococcal conjugated vaccine: PHiD-CV.
Dinleyici EC; Yargic ZA
Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1063-74. PubMed ID: 19883326
[TBL] [Abstract][Full Text] [Related]
31. Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Conjugate Vaccines.
Tejedor JC; Brzostek J; Konior R; Grunert D; Kolhe D; Baine Y; Van Der Wielen M
Clin Vaccine Immunol; 2016 Jul; 23(7):555-63. PubMed ID: 27145999
[TBL] [Abstract][Full Text] [Related]
32. Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugated vaccine (PHiD-CV) co-administered with DTPa-combined vaccines in children: An open-label, randomized, controlled, non-inferiority trial.
Falup-Pecurariu O; Man SC; Neamtu ML; Chicin G; Baciu G; Pitic C; Cara AC; Neculau AE; Burlea M; Brinza IL; Schnell CN; Sas V; Lupu VV; François N; Swinnen K; Borys D
Hum Vaccin Immunother; 2017 Mar; 13(3):649-660. PubMed ID: 27541270
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib and PHiD-CV When Coadministered With MenACWY-TT in Infants: Results of an Open, Randomized Trial.
Merino Arribas JM; Carmona Martínez A; Horn M; Perez Porcuna XM; Otero Reigada MDC; Marès Bermúdez J; Centeno Malfaz F; Miranda M; Mendez M; Garcia Cabezas MA; Christoph W; Bleckmann G; Fischbach T; Kolhe D; Van der Wielen M; Baine Y
Pediatr Infect Dis J; 2018 Jul; 37(7):704-714. PubMed ID: 29620722
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial.
Hammitt LL; Ojal J; Bashraheil M; Morpeth SC; Karani A; Habib A; Borys D; Goldblatt D; Scott JA
PLoS One; 2014; 9(1):e85459. PubMed ID: 24465570
[TBL] [Abstract][Full Text] [Related]
35. Safety and reactogenicity of primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Vietnamese infants: a randomised, controlled trial.
Huu TN; Toan NT; Tuan HM; Viet HL; Le Thanh Binh P; Yu TW; Shafi F; Habib A; Borys D
BMC Infect Dis; 2013 Feb; 13():95. PubMed ID: 23432812
[TBL] [Abstract][Full Text] [Related]
36. Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children.
Dicko A; Santara G; Mahamar A; Sidibe Y; Barry A; Dicko Y; Diallo A; Dolo A; Doumbo O; Shafi F; François N; Strezova A; Borys D; Schuerman L
Hum Vaccin Immunother; 2013 Feb; 9(2):382-8. PubMed ID: 23291945
[TBL] [Abstract][Full Text] [Related]
37. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines.
Chevallier B; Vesikari T; Brzostek J; Knuf M; Bermal N; Aristegui J; Borys D; Cleerbout J; Lommel P; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S109-18. PubMed ID: 19325447
[TBL] [Abstract][Full Text] [Related]
38. Safety, reactogenicity, and immunogenicity of a 12-valent pneumococcal non-typeable
Horn M; Behre U; Traskine M; Dobbelaere K; Borys D
Hum Vaccin Immunother; 2021 May; 17(5):1463-1469. PubMed ID: 33175600
[TBL] [Abstract][Full Text] [Related]
39. Immunization of preterm infants with 10-valent pneumococcal conjugate vaccine.
Omeñaca F; Merino JM; Tejedor JC; Constantopoulos A; Papaevangelou V; Kafetzis D; Tsirka A; Athanassiadou F; Anagnostakou M; François N; Borys D; Schuerman L
Pediatrics; 2011 Aug; 128(2):e290-8. PubMed ID: 21727108
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.
Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Chatfield MD; Lehmann D; Binks M; Chang AB; Carapetis J; Krause V; Andrews R; Snelling T; Skull SA; Licciardi PV; Oguoma VM; Morris PS
Lancet Infect Dis; 2022 Sep; 22(9):1374-1387. PubMed ID: 35772449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]